Protara Therapeutics (TARA) Accumulated Expenses (2013 - 2026)

Protara Therapeutics (TARA) has 14 years of Accumulated Expenses data on file, last reported at $3.6 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 37.8% year-over-year to $3.6 million in Q1 2026; TTM through Mar 2026 was $3.6 million, a 37.8% increase from a year earlier, with the FY2025 full-year figure at $2.7 million, down 2.08% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $3.6 million, up from $2.7 million in the prior quarter.
• Over the last five years, Accumulated Expenses for TARA reached as high as $3.6 million in Q1 2026 and fell as low as $440000.0 in Q4 2023.
• Historically, Accumulated Expenses has averaged $2.3 million across 5 years, with a median of $2.4 million in 2022.
• Across the five-year window, Accumulated Expenses soared 2688.46% in 2022 and slumped 86.41% in 2023, its largest moves.
• Year by year, Accumulated Expenses stood at $3.2 million in 2022, then slumped by 86.41% to $440000.0 in 2023, then soared by 522.73% to $2.7 million in 2024, then fell by 2.08% to $2.7 million in 2025, then surged by 35.18% to $3.6 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $3.6 million in Q1 2026, $2.7 million in Q4 2025, and $2.2 million in Q3 2025.